Riskpilot← Back to searchSign inGet full accessAplex Bio AB
ABActiveOrg 5592482870Nobels Väg 16Research and experimental development on natural sciences and engineering · NACE 7210Est. 20205-9 employees
Revenue 2024
SEK 1,3M
-22% vs 2023
EBITDA margin
-141.3%
-115% vs 2023
Equity ratio
94.8%
Financial strength
Net profit 2024
SEK -1,8M
-115% vs 2023
| Revenue | SEK 1,3M | -22% |
| EBITDA | SEK -1,8M | -115% |
| Net profit | SEK -1,8M | -115% |
| Total assets | SEK 30,3M | +46% |
| Equity | SEK 28,7M | +44% |
| Employees | — | — |
Legal name
Aplex Bio AB
Org number
5592482870
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
17 mars 2020
Share capital
SEK 42 245
Employees
5-9
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Naseem, Umear
Company purpose
Bolaget skall bedriva forskning, utveckling, tillverkning, försäljning och licensiering av kemiska produkter samt molekylär och biomedicinsk diagnostik samt därmed förenlig verksamhet.
Address
Nobels Väg 16
Email
umear@aplex.bio
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 292 | 1 613 | 1 263 |
| Staff expenses | — | — | −3 235 | −4 635 | −5 274 |
| EBITDA | −164 | −430 | −909 | −828 | −1 784 |
| Depreciation & amort. | −0 | −0 | −61 | −99 | −112 |
| EBIT | −164 | −430 | −971 | −927 | −1 896 |
| Net financials | — | — | 4 | 93 | 102 |
| Profit before tax | −164 | −430 | — | −835 | −1 794 |
| Tax | −0 | −0 | — | — | — |
| Net profit | −164 | −430 | −966 | −835 | −1 794 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 6 184 | 14 035 | 13 729 | 20 735 | 30 326 |
| Equity | 5 963 | 13 642 | 12 675 | 20 027 | 28 743 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 221 | 393 | 1 053 | 708 | 1 583 |
| Total debt | 221 | 393 | 1 053 | 708 | 1 583 |
EBITDA margin
-141.3%
This company
15.8%
Market median
-994% vs market
20202024
Equity ratio
94.8%
This company
38.2%
Market median
+148% vs market
20202024
Return on equity
-6.2%
This company
18.4%
Market median
-134% vs market
20202024
Net profit margin
-142.1%
This company
8.1%
Market median
-1854% vs market
20202024
Asset turnover
0.04×
This company
1.12×
Market median
-96% vs market
20202024
Debt / equity
0.06×
This company
0.62×
Market median
+90% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-03-01 – 2020-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
UN Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
ME Audit | Audit | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2020 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Deputy Board Member | 2021 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2024 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Aplex Bio AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Umear Naseem | Chief Executive Officer | 0 companies |
| Marcus Emanuel Öhrn | Audit | 0 companies |
| Nils Henrik Kristoffer Svensson | Deputy Board Member | 0 companies |
| Lina Anna Elisabeth Nordström | Deputy Board Member | 0 companies |
| Zubair Uddin Naseem | Deputy Board Member | 0 companies |
| Mats Bo Johan Nilsson Bernitz | Board of Directors | 0 companies |
| Nina Marika Wodzinski | Board of Directors | 0 companies |
| Henrik Daniel Karlsson | Deputy Board Member | 0 companies |
| Bo Hammarlund | Board of Directors | 0 companies |
| Lars Erik Jonas Wallberg | Chairman | 0 companies |
| Rolf Bertil Ehrnström | Board of Directors | 0 companies |